5.3 Calcium Homeostasis, Dysnatraemia, and Hyperkalaemia Protocols

Key Takeaways

  • Interpret calcium with the laboratory range, ionised calcium when indicated and the PTH result. Severe hypercalcaemia requires treatment of volume depletion and early cause-directed therapy. Bone pain and proximal weakness can occur with vitamin D deficiency even when calcium is in range.

  • Severe or symptomatic hypocalcaemia warrants monitored IV calcium gluconate under the applicable emergency regimen. Check and replace magnesium if low and treat the cause.

  • Severe symptomatic hyponatraemia needs urgent 3% saline. The joint European pathway uses 150 mL over 20 minutes with a monitored initial rise of about 5 mmol/L. Apply time- and risk-specific correction limits.

  • Estimate the water deficit in hypernatraemia, restore perfusion first in shock and adjust the subsequent free-water plan to chronicity and serial sodium.

  • Give IV calcium for hyperkalaemic ECG toxicity, shift potassium and arrange removal. Check potassium for rebound and monitor glucose for at least six hours after insulin under UKKA guidance. Hyperkalaemic arrest uses the distinct ERC regimen.

Last updated: November 2026

Calcium Homeostasis and Disorders of Calcium Metabolism

Total serum calcium comprises three distinct fractions: protein-bound calcium (∼40%\sim 40\%, primarily bound to albumin), complexed calcium (∼10%\sim 10\%, bound to phosphate and citrate), and biologically active, physiologically regulated ionised calcium (∼50%\sim 50\%).

Interpret total and ionised calcium

Albumin changes can affect total calcium independently of ionised calcium. Some laboratories report an adjusted total calcium using a local method. For a calculation exercise that explicitly specifies the simplified Payne formula, use:

Adjusted total calcium (mmol/L)=Measured total calcium (mmol/L)+0.02×(40−Albumin (g/L))\text{Adjusted total calcium (mmol/L)} = \text{Measured total calcium (mmol/L)} + 0.02 \times (40 - \text{Albumin (g/L)})

For example, 2.80+0.02×(40−25)=3.10 mmol/L2.80 + 0.02 \times (40 - 25) = 3.10\text{ mmol/L}. This estimates adjusted total calcium. It does not measure the ionised fraction. Use the laboratory reference range and consider measured ionised calcium if marked hypoalbuminaemia, abnormal pH, critical illness or discordant findings make the estimate unreliable. In malignancy, a calcium concentration above 3.5 mmol/L is a severe presentation. Symptoms and the pace of rise also determine urgency. Calcium adjustment study · Endocrine Society malignancy guideline

Aetiology and Differential Diagnosis of Hypercalcaemia

Primary hyperparathyroidism and malignancy are common causes. PTH separates the initial workup.

  • Elevated or inappropriately normal PTH: Consider primary hyperparathyroidism, often due to a solitary adenoma. Phosphate may be low. Repeat calcium and PTH in a stable patient. Consider familial hypocalciuric hypercalcaemia, particularly in a young patient with lifelong mild hypercalcaemia or a family history. A calcium-to-creatinine clearance ratio below 0.01 favours it but overlaps with primary hyperparathyroidism. Review renal function, vitamin D status and drugs that can affect urinary calcium.
  • Suppressed PTH: Consider malignancy, vitamin D excess and other PTH-independent causes. In malignancy, PTH-related peptide can increase bone resorption and renal calcium reabsorption. Osteolytic metastases or myeloma can increase bone resorption. Some lymphomas produce excess calcitriol.
  • Other contributors: Consider lithium, thiazides, calcium and alkali supplements, granulomatous disease and immobilisation in the appropriate context.

Fifth International Workshop on primary hyperparathyroidism · Endocrine Society malignancy guideline

Clinical Manifestations of Hypercalcaemia

The classical mnemonic "Bones, stones, abdominal groans, and psychiatric moans" summarises the clinical picture:

  • Bones: Bone pain, pathological fractures, osteopenia, osteitis fibrosa cystica;
  • Stones: Nephrolithiasis (calcium oxalate/phosphate stones), nephrocalcinosis, polyuria, and polydipsia (calcium binds calcium-sensing receptors in the collecting duct, inducing nephrogenic diabetes insipidus by downregulating aquaporin-2 water channels);
  • Groans: Anorexia, nausea, vomiting, severe constipation, obstipation, and occasionally pancreatitis;
  • Psychiatric Moans: Lethargy, generalised muscle weakness, fatigue, depression, cognitive impairment, acute delirium, stupor, and coma;
  • Cardiovascular: Shortened QT interval on 12-lead ECG, PR prolongation, hypertension, and malignant ventricular tachyarrhythmias.

Plan care for confirmed primary hyperparathyroidism

Once biochemical primary hyperparathyroidism is confirmed and familial hypocalciuric hypercalcaemia is unlikely, assess bone density, renal function and stone history. Under the Fifth International Workshop, symptoms such as stones support surgical assessment. Even in an asymptomatic adult, a confirmed calcium more than 0.25 mmol/L above the laboratory upper limit, stone or nephrocalcinosis on imaging, impaired renal function below the guideline threshold, an osteoporotic T-score or vertebral fracture, sex-specific hypercalciuria, or age under 50 supports offering parathyroidectomy after specialist review. Localisation imaging is for operative planning, after the decision to pursue surgery. When surgery is deferred, arrange regular follow-up with calcium, vitamin D and renal function at least annually under this guideline, and periodic bone density assessment. Reassess if calcium rises, a kidney stone or fracture develops or renal function worsens.

Fifth International Workshop, recommendations 5, 9 and 10.

Acute management of severe hypercalcaemia

Severe or acutely symptomatic hypercalcaemia requires urgent assessment. Check ECG, renal function, fluid status and electrolytes, and evaluate the mechanism with PTH and further tests as appropriate. Review potentially contributory medicines and supplements.

Restore circulating volume

If volume depleted, start IV 0.9% sodium chloride and reassess blood pressure, urine output, renal function and signs of overload. Polyuria, vomiting and reduced intake can cause major deficits. Choose the volume and rate according to the patient’s haemodynamics and cardiac and renal reserve. Routine loop diuretics can worsen volume depletion. Consider them for fluid overload after volume replacement when appropriate. Society for Endocrinology emergency guidance

Treat the cause and lower calcium

  • Malignancy. Arrange antiresorptive treatment early while addressing volume depletion. Bisphosphonates inhibit osteoclast-mediated resorption, with an effect developing over days. For EU-authorised tumour-induced hypercalcaemia, the Zometa product information lists 4 mg IV as a single dose over at least 15 minutes, with adequate hydration and an indication-specific renal assessment. The renal dosing table for prevention of skeletal events is a separate indication. Discuss agent selection and renal risk with the treating team.
  • Rapid adjunct. In severe malignant hypercalcaemia above 3.5 mmol/L, the Endocrine Society suggests short-course calcitonin with an antiresorptive when available and appropriate. Its rapid effect can bridge the slower effect of an antiresorptive. Tachyphylaxis limits treatment to 48–72 hours in that guideline. Verify the product and local availability and dose with pharmacy.
  • Selected therapies. The Endocrine Society supports denosumab in selected malignant hypercalcaemia. This use is outside Xgeva’s EU-authorised indications. Specialist selection and calcium monitoring are important, particularly in severe renal impairment. In calcitriol-mediated disease such as some lymphomas or granulomatous disease, glucocorticoids address excess calcitriol production. Seek renal or critical-care input for severe refractory hypercalcaemia, major renal failure or inability to give the needed fluids.

Endocrine Society hypercalcaemia guideline · EMA Zometa product information · EMA Xgeva product information

Hypocalcaemia

Use the laboratory reference range and consider measuring ionised calcium when albumin or pH makes total calcium hard to interpret. The Society for Endocrinology treats calcium <1.9 mmol/L or symptoms at any subnormal calcium as severe in its adult emergency guidance.

CauseClinical clues
HypoparathyroidismRecent thyroid or parathyroid surgery. A low or inappropriately normal PTH with low calcium supports the diagnosis.
Vitamin D deficiency or reduced activationNutritional deficiency, malabsorption or advanced CKD. PTH can rise in response.
Magnesium depletionImpaired PTH secretion and response can make hypocalcaemia difficult to correct.
Acute illness and other causesConsider pancreatitis, citrate exposure after transfusion, and antiresorptive medicines in the appropriate context.

Look for perioral or digital paraesthesia, carpopedal spasm, tetany, laryngospasm, seizures or QT prolongation. Trousseau sign is carpal spasm induced by sustained blood pressure cuff inflation above systolic pressure. Chvostek sign is facial twitching after tapping the facial nerve and may also occur in people with normal calcium.

Treat acute symptomatic or severe hypocalcaemia

  1. Stabilise airway and circulation, obtain ECG monitoring and check magnesium, phosphate, kidney function, PTH and vitamin D as indicated. Begin urgent calcium treatment for severe symptoms while investigating the cause.
  2. The Society for Endocrinology adult regimen starts 10–20 mL of 10% calcium gluconate IV diluted in 50–100 mL of 5% glucose over about ten minutes with ECG monitoring. Repeat according to symptoms and protocol. Calcium chloride is more irritating and requires appropriate access. Check the actual preparation and elemental content.
  3. A monitored infusion may be needed after initial treatment. The Society's example uses 100 mL of 10% calcium gluconate diluted in 1 L of 0.9% saline or 5% glucose at 50–100 mL/hour, adjusted to serial calcium and response. Seek renal advice before large-volume infusions in kidney failure.
  4. Replace magnesium if low, using a dose and route appropriate to the deficit and renal function. Treat the cause. Oral calcium and vitamin D treatment may follow. Active vitamin D can be appropriate for hypoparathyroidism or other specialist indications.

Society for Endocrinology adult emergency guidance

Recognise osteomalacia in an adult with bone pain

Osteomalacia is defective mineralisation of newly formed bone. In adults, diffuse bony tenderness, difficulty rising from a chair or climbing stairs, and fragility fractures can suggest osteomalacia. Nutritional vitamin D deficiency, low calcium intake and malabsorption are possible causes. Kidney disease, some medicines and renal phosphate wasting also require consideration. Ask about diet, sunlight exposure, gastrointestinal disease and surgery, and review medicines.

Check 25-hydroxyvitamin D, calcium interpreted with albumin, phosphate, alkaline phosphatase, renal function and PTH. In vitamin D deficiency, secondary hyperparathyroidism can maintain calcium in the laboratory reference range even when bone disease is present. A low 25-hydroxyvitamin D, raised alkaline phosphatase and raised PTH in a patient with the clinical pattern support nutritional osteomalacia. Check whether alkaline phosphatase is of hepatic origin when the context suggests competing liver disease. Persistent hypophosphataemia merits assessment for a phosphate-wasting or other cause. Focal pain may require imaging for a fracture or another local cause. Bone mineral density can be low in osteomalacia and in osteoporosis.

Treat confirmed nutritional deficiency with appropriate vitamin D replacement and ensure adequate calcium intake. Use a clinical treatment regimen and follow-up for symptomatic disease. Usual prevention doses are aimed at people without symptomatic deficiency. Adapt care if malabsorption or organ disease is present and seek specialist advice for unexplained hypophosphataemia or an atypical response.

HSE vitamin D · NHS NENC adult deficiency pathway · International guidance on phosphate-wasting osteomalacia

Follow adults with chronic hypoparathyroidism

Persistent hypocalcaemia with low or inappropriately normal PTH supports the diagnosis after assessment of magnesium and other contributors. Check the cause. After neck surgery, recovery can occur over time, and the 2025 European Society of Endocrinology defines chronic postsurgical disease if it persists beyond 12 months. Once stable, a conventional plan uses active vitamin D with adequate dietary calcium and supplements as needed. Individualise the dose to minimise symptoms and keep serum calcium near the lower limit of normal or slightly below, rather than aiming for high-normal values. Assess for hypercalciuria, even if serum calcium is in range. The guideline uses periodic serum calcium, phosphate, magnesium and kidney monitoring, for example every three to six months, sooner after treatment changes, and 24-hour urine calcium periodically during conventional therapy. Discuss unstable or difficult control with endocrinology.

Revised ESE adult hypoparathyroidism guideline, 2025.

Hyponatraemia

Hyponatraemia is a sodium below 135 mmol/L. Symptom severity and time course determine urgency. A seizure or coma plausibly related to hyponatraemia requires immediate treatment even while the cause and duration are being evaluated.

Determine tonicity and the cause

  1. Check glucose and measured serum osmolality. Hyperglycaemia causes a water shift and can produce hypertonic hyponatraemia. Severe hyperlipidaemia or paraproteinaemia can give pseudohyponatraemia with indirect ion-selective electrodes. A direct electrode measurement can resolve the artefact.
  2. In hypotonic hyponatraemia, interpret urine osmolality and sodium from samples taken near the blood sample. A urine osmolality ≤100 mOsm/kg suggests water intake in excess of solute excretion, such as polydipsia or low solute intake.
  3. If urine osmolality is >100 mOsm/kg, urine sodium ≤30 mmol/L supports low effective arterial volume, which can occur with fluid losses or with congestive heart failure and cirrhosis. Above 30 mmol/L, review diuretics, kidney disease, endocrine causes and clinical volume. Diuretics and kidney disease can obscure urine indices.
  4. Consider SIADH with hypotonic plasma, inappropriately concentrated urine, usually urine sodium >30 mmol/L at normal intake and apparent euvolaemia. Assess adrenal, thyroid and kidney function and recent diuretic exposure before assigning the diagnosis. Causes include small cell lung cancer, pulmonary or CNS disease and medicines such as SSRIs or carbamazepine.

Estimate the glucose effect on measured sodium

Glucose in these formulas is in mmol/L. A conventional Katz estimate adds 1.6 mmol/L sodium for each 5.6 mmol/L glucose above 5.6. The European hyponatraemia guideline uses the Hillier estimate of 2.4 per 5.6 mmol/L. Use the named convention and recognise both are estimates.

Naestimated=Nameasured+c×Glucose−5.65.6\mathrm{Na}_{\text{estimated}} = \mathrm{Na}_{\text{measured}} + c \times \frac{\mathrm{Glucose}-5.6}{5.6}

For sodium 128 and glucose 22.4 mmol/L, the glucose excess is three increments of 5.6. Katz gives 128+3×1.6=132.8128+3\times1.6=132.8 mmol/L and Hillier gives 128+3×2.4=135.2128+3\times2.4=135.2 mmol/L. During treatment of HHS, follow serial measured sodium, osmolality and fluid status under the HHS pathway.

Severe symptomatic hyponatraemia

  • Resuscitate airway and breathing and give 3% saline urgently. The joint European guideline uses 150 mL IV over 20 minutes. Recheck sodium after the bolus and repeat under monitoring up to twice if needed, aiming for an initial rise of about 5 mmol/L and reassessing symptoms.
  • After initial rescue, prevent excess correction. The European guideline limits the rise to 10 mmol/L in the first 24 hours and 8 mmol/L per 24 hours thereafter. In patients at high risk of osmotic demyelination, such as those with very low initial sodium, alcohol use disorder, malnutrition, hypokalaemia or advanced liver disease, use a more conservative plan with senior input. The US/Irish expert panel recommends a ceiling of 8 mmol/L in any 24 hours in this high-risk group, with a daily correction goal of 4–6 mmol/L.
  • Monitor sodium and urine output closely. Correction can accelerate when water diuresis starts or potassium is replaced. If the applicable limit is exceeded or about to be exceeded, stop active correction and seek expert help for controlled relowering with electrolyte-free water and/or desmopressin as appropriate.

SIADH after the emergency

Treat the precipitant and review medicines. Fluid restriction may be first line for stable SIADH. Consider a specialist-directed second-line option such as urea when appropriate. The EU tolvaptan indication covers adult SIADH with hospital initiation and close monitoring. The product is unsuitable for urgent sodium rescue, and European guidance advises against vasopressin antagonists in profound hyponatraemia.

European hyponatraemia guideline · US/Irish hyponatraemia expert panel · Hillier primary study · Adult hyperglycaemic-crisis consensus · Tolvaptan EU label

Hypernatraemia

Hypernatraemia is a serum sodium above 145 mmol/L and usually reflects too little water relative to sodium. Consider impaired access or thirst, insensible or gastrointestinal loss, osmotic diuresis and diabetes insipidus. Lithium, hypercalcaemia and hypokalaemia can impair the renal response to vasopressin. Sodium loading is another possible cause.

Estimate the water deficit

Water deficit (L)=Estimated total body water (L)×(Serum sodium140−1)\text{Water deficit (L)} = \text{Estimated total body water (L)} \times \left(\frac{\text{Serum sodium}}{140}-1\right)

Estimated total body water can start at about 0.6 times body weight in younger men and 0.5 in younger women, with lower fractions in older or depleted patients. For a 60 kg older adult with an estimated fraction of 0.45 and sodium 160 mmol/L, total body water is about 27 L. The estimated deficit is 27×(160/140−1)≈3.927 \times (160/140-1)\approx3.9 L. This is an estimate to reach 140. Plan how much to give over time, and account for ongoing losses and response.

Choose fluid and pace

  • In circulatory shock, restore perfusion first with isotonic crystalloid and reassess. Then replace free water enterally if safe or with IV 5% glucose, adjusting the plan to volume status, glucose and ongoing losses.
  • In chronic or unknown-duration hypernatraemia, a commonly used cautious starting limit is about 0.5 mmol/L/hour or 10–12 mmol/L over 24 hours. Monitor sodium frequently and adjust therapy. The optimal correction rate in adults is uncertain.
  • Acute sodium loading and severe hypernatraemia in a critically ill patient require an individual specialist plan. In hyperglycaemic hyperosmolality, use the HHS pathway and track osmolality as well as sodium.

NHS Ayrshire and Arran hospital guidance · Adult severe hypernatraemia cohort · Adult hospital correction-rate cohort

Hyperkalaemia: Electrocardiographic Staging and 3-Step Protocol

The UKKA adult pathway groups potassium as mild (5.5–5.9 mmol/L), moderate (6.0–6.4 mmol/L) and severe (≥6.5 mmol/L). Compatible ECG changes can indicate toxicity at a lower level. Obtain an ECG promptly and check a repeat specimen if pseudohyperkalaemia is plausible. In a credible emergency with ECG toxicity, start treatment while confirming the result.

Recognise ECG toxicity

Hyperkalaemia alters membrane excitability and conduction. Look for new narrow-based peaked T waves, PR prolongation, flattening or loss of P waves, widening of the QRS, bradyarrhythmia or a sine-wave pattern. Ventricular arrhythmia or cardiac arrest can follow. These findings vary between patients. A normal ECG cannot exclude dangerous hyperkalaemia or justify delaying management of a credible severe result.

UKKA hyperkalaemia guidance · Study of ECG findings in hyperkalaemia

Emergency management of hyperkalaemia

Start cardiac protection when indicated and arrange potassium shift and removal in parallel. Select a regimen for the clinical setting.

StepTreatment and monitoring
Protect the heartWith compatible ECG toxicity, give IV calcium promptly. The HSE safety alert confirms that 30 mL 10% calcium gluconate and 10 mL 10% calcium chloride each supply about 6.8 mmol calcium. Follow the local policy for salt selection. UKKA uses gluconate over ten minutes outside resuscitation and chloride over five minutes in the peri-arrest pathway. Reassess the ECG and repeat calcium if indicated by the response and protocol. Calcium stabilises the heart without lowering potassium.
Shift potassiumFor severe hyperkalaemia the UKKA example uses 10 units soluble insulin with 25 g IV glucose over 15–30 minutes. This glucose dose equals 250 mL of 10%, 125 mL of 20% or 50 mL of 50%. Follow local formulation and access guidance. If baseline glucose is below 7 mmol/L, UKKA then gives 10% glucose at 50 mL/hour for five hours. Nebulised salbutamol 10–20 mg is an adjunct.
Remove potassiumArrange urgent renal assessment for severe hyperkalaemia in maintenance haemodialysis or when potassium is refractory. Give calcium for toxic ECG changes even if dialysis is immediately available. An oral binder can be an adjunct. UKKA uses sodium zirconium cyclosilicate 10 g three times daily for correction for up to 72 hours. Patiromer has a slower onset. Consider diuretics only in appropriate patients with urine output, with attention to volume status.

Arrest. ERC 2025 uses 10 mL of 10% calcium chloride IV plus 50 mmol IV sodium bicarbonate in hyperkalaemic cardiac arrest, through separate lines or with a flush between them. This accompanies standard resuscitation and the potassium treatment pathway. Avoid routine bicarbonate for non-arrest hyperkalaemia.

Monitor for rebound and hypoglycaemia. After insulin, the UKKA schedule checks glucose at baseline, at 30, 60, 90 and 120 minutes, then hourly through six hours. Extend monitoring if risk remains high. Recheck potassium early according to severity and response. UKKA suggests at least 1, 2, 4, 6 and 24 hours for moderate or severe episodes. Review supplements and medicines that increase potassium, and make an individual restart plan for indicated long-term therapies.

HSE calcium safety alert · UKKA hyperkalaemia guidance · ERC special circumstances · Lokelma EU label · Veltassa EU label

Test Your Knowledge

A 66-year-old man with end-stage renal disease on maintenance haemodialysis presents to the emergency department after missing his last two dialysis sessions. His 12-lead ECG reveals tall, peaked T waves across leads V2 to V5, marked PR interval prolongation (280 ms), and QRS complex widening (140 ms). He is conscious and haemodynamically stable. The department uses the UKKA calcium regimen for hyperkalaemia with ECG changes outside peri-arrest. Point-of-care testing shows a potassium level of 7.4 mmol/L. What is the most appropriate immediate pharmacological intervention to administer first?

A

Administer 10 units of soluble human insulin in 50 mL of 50% dextrose intravenously over 20 minutes

B

Administer 20 mg of nebulized salbutamol driven by high-flow oxygen

C

Administer 30 mL of 10% calcium gluconate IV over 10 minutes with continuous cardiac monitoring.

D

Administer 10 g of oral sodium zirconium cyclosilicate (Lokelma) dissolved in water

Test Your Knowledge

A 48-year-old woman with small cell lung cancer is brought to the hospital by ambulance after experiencing a witnessed 2-minute generalized tonic-clonic seizure. On examination, she is comatose (Glasgow Coma Scale 6: E1V1M4) with shallow respirations. Urgent biochemistry reveals: serum sodium 112 mmol/L, potassium 3.8 mmol/L, urea 3.2 mmol/L, serum osmolality 236 mOsm/kg, urine osmolality 480 mOsm/kg, urine sodium 64 mmol/L and glucose 5.0 mmol/L. The duration of hyponatraemia is unknown and SIADH is suspected. Airway support is underway. Under the joint European adult guideline, what is the next intervention and immediate sodium goal?

A

Initiate strict fluid restriction to 500 mL/24 hours and observe neurological recovery over 48 hours without hypertonic saline

B

Administer an intravenous infusion of 0.9% sodium chloride at 250 mL/hour targeting a serum sodium increase of 15 mmol/L in the first 12 hours

C

Administer oral tolvaptan 15 mg once daily combined with 20 mg intravenous furosemide

D

Give 150 mL of 3% saline IV over 20 minutes, recheck sodium and reassess symptoms. Aim initially for an increase of about 5 mmol/L.

Test Your Knowledge

A 64-year-old man with metastatic squamous cell carcinoma of the lung is admitted with progressive lethargy, confusion, constipation, and polyuria. Physical examination reveals marked dehydration with dry mucous membranes and poor skin turgor. Laboratory evaluation reveals: serum adjusted calcium 3.84 mmol/L, serum phosphate 0.72 mmol/L, serum creatinine 192 µmol/L (baseline 85 µmol/L), and serum intact PTH 4 pg/mL (suppressed). An ECG demonstrates a shortened QT interval (QTc 340 ms). What is the most appropriate initial management step?

A

Administer an immediate intravenous bolus of furosemide 80 mg to accelerate renal calcium excretion

B

Initiate oral prednisolone 60 mg daily and perform emergency neck exploration for parathyroidectomy

C

Start IV 0.9% sodium chloride for hypovolaemia, reassess fluid tolerance and arrange early calcium-lowering therapy.

D

Administer intravenous zoledronic acid 4 mg immediately as monotherapy without intravenous fluid rehydration

Test Your Knowledge

A 59-year-old with limited dietary intake and little sunlight exposure has diffuse bone tenderness and difficulty standing from a chair. Testing shows markedly low 25-hydroxyvitamin D, elevated alkaline phosphatase and PTH, normal adjusted calcium and low phosphate. Which diagnosis best fits?

A

Vitamin D deficiency osteomalacia with secondary hyperparathyroidism

B

Primary hypoparathyroidism

C

Uncomplicated osteoporosis

D

Primary hyperparathyroidism already established by the PTH result alone

Test Your Knowledge

A 63-year-old has confirmed primary hyperparathyroidism. Adjusted calcium is 2.89 and 2.91 mmol/L on separate visits, with a laboratory upper limit of 2.60 mmol/L. There is no acute illness. Under the Fifth International Workshop guidance, what is appropriate?

A

Discuss referral for parathyroid surgical assessment because the elevation exceeds 0.25 mmol/L above the upper limit

B

Wait for a kidney stone before discussing referral

C

Give IV saline and calcitonin immediately for a severe malignancy-related emergency

D

Request localisation imaging as the diagnostic test for primary hyperparathyroidism

Test Your Knowledge

A patient with chronic postsurgical hypoparathyroidism takes calcitriol and calcium. They feel well and adjusted calcium is just within the lower laboratory limit. They ask whether the doses should be increased to reach the upper limit. What is appropriate?

A

Increase calcium and calcitriol until calcium is high-normal, then stop urine monitoring

B

Keep an individualised low-normal calcium target and continue serum and urine monitoring under the treatment plan

C

Switch directly to parathyroid surgery to raise serum calcium

D

Stop all follow-up because the patient has no symptoms

Sections you finish are checked off in the contents.